COVID-19 infection and rheumatoid arthritis: Faraway, so close!
Autoimmun Rev
; 19(5): 102523, 2020 May.
Article
in English
| MEDLINE | ID: covidwho-13932
ABSTRACT
The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Arthritis, Rheumatoid
/
Immunocompromised Host
/
Coronavirus Infections
/
Antirheumatic Agents
/
Betacoronavirus
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Autoimmun Rev
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS